QIAGEN Stock Gains Following the Acquisition of Genoox
QIAGEN N.V. QGEN recently signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests.
The latest acquisition aims to bolster QIAGEN's next-generation sequencing (NGS) portfolio.
Following the announcement, shares of the company moved north 2.3% to $42.96 yesterday.
Over the past few quarters, the company has continuously integrated AI technology into the QDI portfolio. In 2024, QIAGEN introduced a new version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), to deliver significant performance and scalability enhancements for high-throughput, NGS labs transitioning to larger test panels and higher test volumes. The company also launched QCI Secondary Analysis — a cloud-based software-as-a-service (SaaS) solution that enables high-throughput secondary analysis for use with any clinical next-generation sequencing (NGS) data. Accordingly, we expect the latest acquisition of Genoox to bolster investor confidence and maintain an upward momentum in QGEN's share price in the upcoming days.
QIAGEN currently has a market capitalization of $9.28 billion. The company delivered an average earnings surprise of 4.93% for the trailing four quarters.
QIAGEN acquired Genoox for $70 million in cash, and is eligible for additional milestone payments of up to $10 million. The acquisition is expected to generate approximately $5 million in sales for QIAGEN in 2025 and have a neutral impact on adjusted earnings per share (EPS).
The acquisition adds Franklin — Genoox's flagship cloud-based community platform — to the QIAGEN Digital Insights (QDI) portfolio. It further strengthens QIAGEN's leadership in genetic interpretation for clinical genomics applications.
Franklin empowers labs to analyze next-generation sequencing (NGS) data from targeted gene panels to whole exome and genome sequencing (WES/WGS). It delivers real-time, AI-driven insights to support clinical decision-making. Franklin is currently used by over 4,000 healthcare organizations in more than 50 countries and has powered over 750,000 case interpretations to date.
Image Source: Zacks Investment Research
The acquisition paves the way to integrate QIAGEN's genomic content into the Franklin platform. This includes the Human Gene Mutation Database, the Catalogue of Somatic Mutations in Cancer and the QIAGEN Knowledge Base, all of which power the company's leading QCI Interpret and QCI Precision Insights solutions.
Per a report by MarketsandMarkets, the global NGS market size was valued at $12.13 in 2023 and is expected to witness a compound annual growth rate (CAGR) of 13.2% from 2024 to 2029. The market is experiencing significant growth, driven by the rising demand for precision medicine and the confluence of technological advancements.
The company expanded its cell and gene therapy (CGT) portfolio in the previous month with an enhanced digital PCR (dPCR) workflow that includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as chimeric antigen receptor T-cell (CAR-T) therapies.
In the past year, QGEN's shares have lost 8% compared with the industry's 21.4% decline.
The company currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are AngioDynamics ANGO, STERIS STE and DexCom DXCM.
AngioDynamics, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated earnings growth rate of 23.7% for 2025. You can see the complete list of today's Zacks #1 Rank stocks here.
ANGO's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 70.85%. Veracyte's shares have risen 49.2% in the past year compared with the industry's 5.5% growth.
STERIS, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 10.8% for 2025.
STE's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 0.61%. Its shares have risen 34.1% compared with the industry's 7.7% growth in the past year.
DexCom, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 23.2% for 2025. Its earnings surpassed estimates in two of the trailing four quarters and missed in the other two, delivering an average surprise of 0.47%.
DXCM's shares have risen 26.4% against the industry's 15.7% decline in the past year.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
QIAGEN N.V. (QGEN) : Free Stock Analysis Report
STERIS plc (STE) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Humans provide necessary 'checks and balances' for AI, says Lattice CEO
Of all the words in the dictionary, Sarah Franklin says 'balance' is perhaps her favorite -- especially when it comes to companies embracing AI. Franklin leads the Jack Altman-founded employee performance software company Lattice, which is now worth $3 billion. Both onstage at SXSW London and in conversation with TechCrunch, she spoke a lot about balance — the opportunities in finding it, and the risks of not having it during this AI revolution. 'We put people first,' Franklin told TechCrunch, referring to Lattice, which has started to adopt more AI and automation features. Although some companies are touting AI as a way to replace massive numbers of workers, some tech leaders are speaking more openly about the importance of striking a balance at their companies: retaining human employees while augmenting them with AI assistants and 'agents.' At SXSW London, Franklin said that looking to fully replace human workers might seem like a good idea in the short term for cost-saving reasons, but such a move might not actually be attractive to customers. 'It's important to ask yourself, 'Are you building for the success of the AI first [or are] you building for the success of the people and your customers first?' she said, adding that trust is the most important currency any founder or startup company has, and that building trust with consumers is paramount. 'It's good to have efficiency, but you don't want to trade out trust.' Franklin also stressed the importance of transparency, accountability, and responsibility when it comes to AI. Leaders need to be transparent with employees about what the AI is doing, the AI must be narrowly applied to a particular goal so people understand how it works, and humans must ultimately be held accountable for what the AI impacts. 'Otherwise, we are then in service of the AI versus the AI being in service of us,' Franklin continued. In an interview with TechCrunch after her SXSW appearance, Franklin said Lattice has built an AI HR agent that gives proactive insights and assists employees in one-on-one meetings. The company also has a platform where Lattice clients can create their own custom agents for their businesses. Franklin was adamant that humans must have oversight of any AI technology implemented by a company. 'It's a way to just have the regular checks and balances that we're used to in our workforce,' she told TechCrunch. She thinks the victors in this AI moment in history will be the ones who learn how to put people first. According to Franklin, it's one of the most important guardrails that a company can have on AI. 'We all have a responsibility to make sure that we're doing this for the people of society,' Franklin said. 'Human connection cannot be replaced, and the winners are going to be the companies that understand that.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Qiagen (QGEN). Shares have added about 8.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Qiagen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. It turns out, fresh estimates have trended upward during the past month. The consensus estimate has shifted 6.92% due to these changes. Currently, Qiagen has a nice Growth Score of B, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy. Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Qiagen has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months. Qiagen belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Incyte (INCY), has gained 12.6% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025. Incyte reported revenues of $1.05 billion in the last reported quarter, representing a year-over-year change of +19.5%. EPS of $1.16 for the same period compares with $0.64 a year ago. For the current quarter, Incyte is expected to post earnings of $1.38 per share, indicating a change of +175.8% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.6% over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Incyte. Also, the stock has a VGM Score of A. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Incyte Corporation (INCY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
3 days ago
- Yahoo
Humans provide necessary 'checks and balances' for AI, says Lattice CEO
Of all the words in the dictionary, Sarah Franklin says 'balance' is perhaps her favorite -- especially when it comes to companies embracing AI. Franklin leads the Jack Altman-founded employee performance software company Lattice, which is now worth $3 billion. Both onstage at SXSW London and in conversation with TechCrunch, she spoke a lot about balance — the opportunities in finding it, and the risks of not having it during this AI revolution. 'We put people first,' Franklin told TechCrunch, referring to Lattice, which has started to adopt more AI and automation features. Although some companies are touting AI as a way to replace massive numbers of workers, some tech leaders are speaking more openly about the importance of striking a balance at their companies: retaining human employees while augmenting them with AI assistants and 'agents.' At SXSW London, Franklin said that looking to fully replace human workers might seem like a good idea in the short term for cost-saving reasons, but such a move might not actually be attractive to customers. 'It's important to ask yourself, 'Are you building for the success of the AI first [or are] you building for the success of the people and your customers first?' she said, adding that trust is the most important currency any founder or startup company has, and that building trust with consumers is paramount. 'It's good to have efficiency, but you don't want to trade out trust.' Franklin also stressed the importance of transparency, accountability, and responsibility when it comes to AI. Leaders need to be transparent with employees about what the AI is doing, the AI must be narrowly applied to a particular goal so people understand how it works, and humans must ultimately be held accountable for what the AI impacts. 'Otherwise, we are then in service of the AI versus the AI being in service of us,' Franklin continued. In an interview with TechCrunch after her SXSW appearance, Franklin said Lattice has built an AI HR agent that gives proactive insights and assists employees in one-on-one meetings. The company also has a platform where Lattice clients can create their own custom agents for their businesses. Franklin was adamant that humans must have oversight of any AI technology implemented by a company. 'It's a way to just have the regular checks and balances that we're used to in our workforce,' she told TechCrunch. She thinks the victors in this AI moment in history will be the ones who learn how to put people first. According to Franklin, it's one of the most important guardrails that a company can have on AI. 'We all have a responsibility to make sure that we're doing this for the people of society,' Franklin said. 'Human connection cannot be replaced, and the winners are going to be the companies that understand that.' Error in retrieving data Sign in to access your portfolio Error in retrieving data
